The move toward targeted anti-cancer treatments has produced better outcomes with fewer side-effects for many breast cancer patients. But so far, advances in precision medicine haven’t reached people diagnosed with so-called triple-negative breast cancer. An innovative compound developed in the lab of Scripps Research chemist Matthew D. Disney, Ph.D., offers a new potential route to